ArticleNature metabolism2022
Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution.
Open access · greenAbstract read
In one paragraph
Article in Nature metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 159 citations in OpenAlex.
- Resolving the links between efferocytosis and DNMT3A mutation-driven clonal hematopoiesis in atherosclerosis.The Journal of clinical investigation · 2026Article
- Efferocytosis activates a DNMT3A-mediated oxidized DNA repair pathway to enable tissue resolution.The Journal of clinical investigation · 2026Article
- Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution inCirculation · 2026Article
- Article
- Review
- A bioorthogonal nanoconcentrisome system for epigenetic and immunometabolic reprogramming of tissue regeneration in aged female rats.Nature communications · 2026Article
- Defective efferocytosis in diabetes: molecular mechanisms and emerging therapeutic strategies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- ERK1/2 activation in anti-inflammatory effects and underlying signaling mechanisms.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Metabolic Perspective on Atherosclerosis: Macrophage Reprogramming and Novel Therapeutic Targets.Journal of the American Heart Association · 2026Review
- Amino Acids as Targets for Immunotherapy against Solid Tumors.Cell biochemistry and biophysics · 2026Review
- Parabacteroides goldsteinii and its metabolite 7-KLCA attenuate endometriosis via TGR5 to reprogram macrophages by modulating the PPARγ/GPR132 axis.NPJ biofilms and microbiomes · 2026Article
- Macrophage efferocytosis promotes inflammation resolution and accelerates wound healing.Communications biology · 2026Review
- Review
- From lipoprotein metabolism to blood clotting: Highlights of the 2025 Fredrickson lipid research conference.Journal of lipid research · 2026Article
- CD47 Blockade Reprograms the Monocyte-Macrophage Axis to Promote Inflammation Resolution in Atherosclerosis.bioRxiv : the preprint server for biology · 2026Article
- Obesity Disrupts H3K4me3-Mediated Lactate Accumulation and Efferocytosis in Hypoxic Macrophages.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Agonal cell resuscitation strategy to promote tissue repair.Nature communications · 2026Article
- Lysosomal cholesteryl ester hydrolysis drives white matter repair by reprogramming microglia into a novel reparative state.Journal of neuroinflammation · 2026Article
- Polystyrene microplastic-induced pathophysiology is driven by disruption of efferocytosis.Immunity · 2026Article
- Modulation of immune cells and metabolic reprogramming in efferocytosis.Cell death & disease · 2026Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 7 institutions in 2 countries.
Patrick B AmpomahDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA. pbampomah1@gmail.com.ORCID http://orcid.org/0000-0003-0561-1145
Bishuang CaiDivision of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Santosh R SukkaDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Brennan D GerlachNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Arif YurdagulDepartment of Molecular and Cellular Physiology, LSU Health Shreveport, Shreveport, LA, USA.
Xiaobo WangDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-6044-914X
George KuriakoseDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Lancia N F DarvilleProteomics and Metabolomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Yan SunDepartment of Biochemistry, Albert Einstein College of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-5747-3306
Simone SidoliDepartment of Biochemistry, Albert Einstein College of Medicine, New York, NY, USA.
John M KoomenProteomics and Metabolomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-3818-1762
Alan R TallDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Ira TabasDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA. iat1@columbia.edu.ORCID http://orcid.org/0000-0003-3429-1515
Columbia University Irving Medical Center · USAlbert Einstein College of Medicine · USMoffitt Cancer Center · USIcahn School of Medicine at Mount Sinai · USLouisiana State University Health Sciences Center Shreveport · USNovartis (Switzerland) · CHNovartis (United States) · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MTTC39B in obesity and atherosclerosisP01HL087123 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI TABAS, IRA A · 2007 to 2022
$31.2MPOSTDOCTORAL TRAINING IN ARTERIOSCLEROSIS RESEARCHT32HL007343 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI HENRY N GINSBERG, Muredach P Reilly · 1985 to 2026
$12.7MA Mechanistic and Translational Research Program Linking Impaired Resolution, Defective Efferocytosis, and Clonal Hematopoiesis to the Formation of Clinically Dangerous Atherosclerotic PlaquesR35HL145228 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI TABAS, IRA A · 2019 to 2025
$6.8MClonal hematopoiesis, inflammasomes and atherosclerosisR01HL155431 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALAN richard TALL · 2021 to 2026
$3.7MEnhancing Inflammation Resolution in Atherosclerosis via Targeted Nanoparticle-Mediated Delivery of BiologicsR01HL127464 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHI, JINJUN, TABAS, IRA A · 2016 to 2019
$3.0MHow MeCP2 discriminates epigenetic marks is still a mysteryR01GM129350 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI BRENOWITZ, MICHAEL D. · 2018 to 2021
$1.3MMerTK in NASH-related liver fibrosisR00DK115778 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, BISHUANG · 2020 to 2022
$747kProcessing of Apoptotic Cell-Derived Cargo by Macrophages Continues Efferocytosis and Drives Atherosclerosis RegressionR00HL145131 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI YURDAGUL, ARIF · 2021 to 2023
$747kBD Biosciences InfluxS10OD020056 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SNOECK, HANS-WILLEM E · 2015 to 2015
$600kOrbitrap Exploris 480 Basic SystemS10OD030286 · OD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SIDOLI, SIMONE · 2021 to 2021
$600kNCI NIH HHS P30 CA013696NCI NIH HHS P30 CA076292NCRR NIH HHS S10 RR027050NHLBI NIH HHS K99 HL145131NHLBI NIH HHS P01 HL087123NHLBI NIH HHS R00 HL145131NHLBI NIH HHS R01 HL127464NHLBI NIH HHS R01 HL155431NHLBI NIH HHS R35 HL145228NHLBI NIH HHS T32 HL007343NIDDK NIH HHS R00 DK115778NIGMS NIH HHS R01 GM129350NIH HHS S10 OD020056NIH HHS S10 OD030286
Abstract
Efferocytosis, the clearance of apoptotic cells (ACs) by macrophages, is critical for tissue resolution, with defects driving many diseases. Mechanisms of efferocytosis-mediated resolution are incompletely understood. Here, we show that AC-derived methionine regulates resolution through epigenetic repression of the extracellular signal-regulated kinase 1/2 (ERK1/2) phosphatase Dusp4. We focus on two key efferocytosis-induced pro-resolving mediators, prostaglandin E
Indexed as
MethionineTransforming Growth Factor beta1AnimalsApoptosisCyclooxygenase 2DNA Methyltransferase 3AMacrophagesMiceProstaglandins ECyclooxygenase 2DNA Methyltransferase 3ADnmt3a protein, mouseMethionineProstaglandins ETransforming Growth Factor beta1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.